This year’s meeting will include over 200 sessions, complementing Yale Cancer Center director and Smilow physician-in-chief, Dr. Eric Winer’s ASCO presidential theme, “Partnering With Patients: The Cornerstone of Cancer Care and Research.” Dr. Winer, the 2022-2023 ASCO President, will host the 2023 ASCO Meeting opening session and educational sessions in cancer research.
Some of the key presentations from Yale include:
Oral Abstract Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant: IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesi. Senior Author: Amer Zeidan, MBBS. June 2 —3:12 PM
Plenary Session: Special Sessions | Central Nervous System Tumors | Gastrointestinal Cancer—Colorectal and Anal | Lung Cancer | Hematologic Malignancies: Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). Presenter: Roy S. Herbst, MD, PhD. June 4 —3:17 PM
Plenary Session: Special Sessions | Central Nervous System Tumors | Gastrointestinal Cancer—Colorectal and Anal | Lung Cancer | Hematologic Malignancies: Panel Question and Answer. Moderator: Eric Winer, MD. June 4 — 3:17 PM
Abstract Discussion: Breast Cancer – Local/Regional/Adjuvant: Are We Splitting HERs? The Highs and Lows. Presenter: David Rimm, MD, PhD. June 4 —5:30 PM
Poster Session: Gynecologic Cancer: Racial and ethnic disparities in quality of diagnostic evaluation for uterine cancer among Medicare patients. Speaker: Xiao Xu, PhD, MA. June 5 —2:15 PM
Poster Session: Care Delivery and Regulatory Policy: Trends in new and persistent opioid use in older adults with cancer. Presenter: Henry Soo-Min Park, MD, MPH. June 5 — 2:15 PM
Oral Abstract Session: Breast Cancer—Metastatic: An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03. Speaker: Ian Krop, MD, PhD. June 5 —2:30 PM
A full list of Yale Cancer Center and Smilow Cancer Hospital presenters at ASCO and schedule of events can be found here.